SE9503620L - Användning av proteinet S-100b för framställning av läkemedel för nervceller - Google Patents

Användning av proteinet S-100b för framställning av läkemedel för nervceller

Info

Publication number
SE9503620L
SE9503620L SE9503620A SE9503620A SE9503620L SE 9503620 L SE9503620 L SE 9503620L SE 9503620 A SE9503620 A SE 9503620A SE 9503620 A SE9503620 A SE 9503620A SE 9503620 L SE9503620 L SE 9503620L
Authority
SE
Sweden
Prior art keywords
protein
pct
drugs
manufacture
nerve cells
Prior art date
Application number
SE9503620A
Other languages
Unknown language ( )
English (en)
Other versions
SE505316C3 (sv
SE505316C2 (sv
SE9503620D0 (sv
Inventor
Kenneth G Haglid
Original Assignee
Kenneth G Haglid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth G Haglid filed Critical Kenneth G Haglid
Priority to SE9503620A priority Critical patent/SE505316C2/sv
Publication of SE9503620D0 publication Critical patent/SE9503620D0/sv
Priority to JP9515742A priority patent/JPH11515003A/ja
Priority to CZ981166A priority patent/CZ116698A3/cs
Priority to AU73523/96A priority patent/AU713332B2/en
Priority to CA002235278A priority patent/CA2235278A1/en
Priority to EE9800108A priority patent/EE9800108A/xx
Priority to US09/051,589 priority patent/US5990080A/en
Priority to NZ320721A priority patent/NZ320721A/en
Priority to EP96935706A priority patent/EP0952844A1/en
Priority to PCT/SE1996/001305 priority patent/WO1997014427A1/en
Publication of SE505316C3 publication Critical patent/SE505316C3/sv
Publication of SE9503620L publication Critical patent/SE9503620L/sv
Publication of SE505316C2 publication Critical patent/SE505316C2/sv
Priority to NO981719A priority patent/NO981719L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9503620A 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller SE505316C2 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller
PCT/SE1996/001305 WO1997014427A1 (en) 1995-10-17 1996-10-15 USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
CZ981166A CZ116698A3 (cs) 1995-10-17 1996-10-15 Použití proteinu S-100 v medicíně a léčivo obsahující protein S100-b
JP9515742A JPH11515003A (ja) 1995-10-17 1996-10-15 タンパク質Ｓ−１００ｂの薬剤への使用法、および該タンパク質Ｓ−１００ｂを含む薬剤
AU73523/96A AU713332B2 (en) 1995-10-17 1996-10-15 Use of protein S-100b in medicines and medicines containing the protein S-100-b
CA002235278A CA2235278A1 (en) 1995-10-17 1996-10-15 Use of protein s-100b in medicines and medicines containing the protein s-100b
EE9800108A EE9800108A (et) 1995-10-17 1996-10-15 Valgu S-100b kasutamine ravimites ja valku S-100b sisaldavad ravimid
US09/051,589 US5990080A (en) 1995-10-17 1996-10-15 Use of protein S-100-b in medicines containing the protein S-100b
NZ320721A NZ320721A (en) 1995-10-17 1996-10-15 Use of the S-100b protein as a medicine to treat amyotrophic lateral sclerosis or multiple sclerosis
EP96935706A EP0952844A1 (en) 1995-10-17 1996-10-15 USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
NO981719A NO981719L (no) 1995-10-17 1998-04-16 Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller

Publications (4)

Publication Number Publication Date
SE9503620D0 SE9503620D0 (sv) 1995-10-17
SE505316C3 SE505316C3 (sv) 1997-04-18
SE9503620L true SE9503620L (sv) 1997-04-18
SE505316C2 SE505316C2 (sv) 1997-08-04

Family

ID=20399846

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9503620A SE505316C2 (sv) 1995-10-17 1995-10-17 Användning av proteinet S-100b för framställning av läkemedel för nervceller

Country Status (11)

Country Link
US (1) US5990080A (sv)
EP (1) EP0952844A1 (sv)
JP (1) JPH11515003A (sv)
AU (1) AU713332B2 (sv)
CA (1) CA2235278A1 (sv)
CZ (1) CZ116698A3 (sv)
EE (1) EE9800108A (sv)
NO (1) NO981719L (sv)
NZ (1) NZ320721A (sv)
SE (1) SE505316C2 (sv)
WO (1) WO1997014427A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258776B1 (en) * 1997-08-12 2001-07-10 Novartis Ag Calcium-regulated kinase
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (ja) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
US7351686B2 (en) * 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons

Also Published As

Publication number Publication date
AU713332B2 (en) 1999-12-02
JPH11515003A (ja) 1999-12-21
SE505316C2 (sv) 1997-08-04
NO981719L (no) 1998-06-16
CA2235278A1 (en) 1997-04-24
US5990080A (en) 1999-11-23
EP0952844A1 (en) 1999-11-03
WO1997014427A1 (en) 1997-04-24
SE9503620D0 (sv) 1995-10-17
NZ320721A (en) 2000-07-28
EE9800108A (et) 1998-10-15
CZ116698A3 (cs) 1998-09-16
AU7352396A (en) 1997-05-07
NO981719D0 (no) 1998-04-16

Similar Documents

Publication Publication Date Title
DE59610355D1 (de) Medizinisches implantat
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
ES2184895T3 (es) Sistema no polimerico de administracion con liberacion retardada.
DE69530919D1 (de) Beigeordnetes polymersystem zur verwendung mit einer medizinischen vorrichtung
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
TW326394B (en) Insulin formulation
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
FI952701A0 (sv) Process för behandling av en metallisk kirurgisk implantat
SG52240A1 (en) The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
MY112915A (en) Multiple unit tableted dosage form 1
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
DE69922143D1 (de) Implantierbares system mit medikamentenabgebenden zellen zur lokalen verabreichung von medikamenten bei bedarf
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
DE69400435D1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
SE9503620L (sv) Användning av proteinet S-100b för framställning av läkemedel för nervceller
UA26845C2 (uk) Похідhі пептидів, що є аhтагоhістами речовиhи р та hейрокіhіhу а
AU4949993A (en) Drugs containing diphosphonic acids and salts thereof
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
RU98109592A (ru) Применение белка s-100b в лекарственных средствах и лекарственные средства, содержащие белок s-100b
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9503620-8

Format of ref document f/p: F